ALK-Abelló A/S (ALK-B) - Total Assets
Based on the latest financial reports, ALK-Abelló A/S (ALK-B) holds total assets worth Dkr9.17 Billion DKK (≈ $1.44 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check ALK-Abelló A/S cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
ALK-Abelló A/S - Total Assets Trend (2005–2025)
This chart illustrates how ALK-Abelló A/S's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of ALK-Abelló A/S to see how much of total assets are deployed in long-term investments.
ALK-Abelló A/S - Asset Composition Analysis
Current Asset Composition (December 2025)
ALK-Abelló A/S's total assets of Dkr9.17 Billion consist of 49.0% current assets and 51.0% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 13.5% |
| Accounts Receivable | Dkr1.34 Billion | 14.6% |
| Inventory | Dkr1.78 Billion | 19.4% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr1.31 Billion | 14.3% |
| Goodwill | Dkr455.00 Million | 5.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how ALK-Abelló A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALK-B company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ALK-Abelló A/S's current assets represent 49.0% of total assets in 2025, a decrease from 87.6% in 2005.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 80.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 2.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 19.4% of total assets.
ALK-Abelló A/S Competitors by Total Assets
Key competitors of ALK-Abelló A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Camurus AB
ST:CAMX
|
Sweden | Skr4.74 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Disc Medicine Inc.
NASDAQ:IRON
|
USA | $750.21 Million |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
ALK-Abelló A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.38 | 1.69 | 2.33 |
| Quick Ratio | 2.04 | 0.81 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr3.17 Billion | Dkr1.34 Billion | Dkr1.44 Billion |
ALK-Abelló A/S - Advanced Valuation Insights
This section examines the relationship between ALK-Abelló A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.72 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | 11.2% |
| Total Assets | Dkr9.17 Billion |
| Market Capitalization | $8.52 Billion USD |
Valuation Analysis
Near Book Valuation: The market values ALK-Abelló A/S's assets close to their book value (0.93x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: ALK-Abelló A/S's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ALK-Abelló A/S (2005–2025)
The table below shows the annual total assets of ALK-Abelló A/S from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr9.17 Billion ≈ $1.44 Billion |
+11.23% |
| 2024-12-31 | Dkr8.25 Billion ≈ $1.29 Billion |
+22.60% |
| 2023-12-31 | Dkr6.73 Billion ≈ $1.05 Billion |
+6.63% |
| 2022-12-31 | Dkr6.31 Billion ≈ $986.93 Million |
+8.20% |
| 2021-12-31 | Dkr5.83 Billion ≈ $912.15 Million |
+4.80% |
| 2020-12-31 | Dkr5.56 Billion ≈ $870.37 Million |
+1.24% |
| 2019-12-31 | Dkr5.50 Billion ≈ $859.73 Million |
+12.95% |
| 2018-12-31 | Dkr4.87 Billion ≈ $761.16 Million |
-1.88% |
| 2017-12-31 | Dkr4.96 Billion ≈ $775.72 Million |
+3.31% |
| 2016-12-31 | Dkr4.80 Billion ≈ $750.84 Million |
+12.86% |
| 2015-12-31 | Dkr4.25 Billion ≈ $665.26 Million |
+24.36% |
| 2014-12-31 | Dkr3.42 Billion ≈ $534.93 Million |
+4.62% |
| 2013-12-31 | Dkr3.27 Billion ≈ $511.30 Million |
-0.43% |
| 2012-12-31 | Dkr3.28 Billion ≈ $513.49 Million |
-2.15% |
| 2011-12-31 | Dkr3.35 Billion ≈ $524.76 Million |
+18.52% |
| 2010-12-31 | Dkr2.83 Billion ≈ $442.77 Million |
+6.67% |
| 2009-12-31 | Dkr2.65 Billion ≈ $415.08 Million |
+4.53% |
| 2008-12-31 | Dkr2.54 Billion ≈ $397.09 Million |
-10.03% |
| 2007-12-31 | Dkr2.82 Billion ≈ $441.37 Million |
+1.15% |
| 2006-12-31 | Dkr2.79 Billion ≈ $436.36 Million |
-59.67% |
| 2005-12-31 | Dkr6.92 Billion ≈ $1.08 Billion |
-- |
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more